{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:20:16Z","timestamp":1786119616216,"version":"build-2736575974"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,3]]},"DOI":"10.1097\/md.0b013e318211106a","type":"journal-article","created":{"date-parts":[[2011,2,25]],"date-time":"2011-02-25T03:29:25Z","timestamp":1298604565000},"page":"139-145","source":"Crossref","is-referenced-by-count":68,"title":["TNF-\u03b1 Antagonist Use and Risk of Hospitalization for Infection in a National Cohort of Veterans With Rheumatoid Arthritis"],"prefix":"10.1097","volume":"90","author":[{"given":"Michael A.","family":"Lane","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay R.","family":"McDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelique L.","family":"Zeringue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liron","family":"Caplan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey R.","family":"Curtis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prabha","family":"Ranganathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth A.","family":"Eisen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-7-20210226","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1093\/rheumatology\/41.12.1367","article-title":"The rheumatoid arthritis patient in the clinic: comparing more than 1300 consecutive DMARD courses.","volume":"41","author":"Aletaha","year":"2002","journal-title":"Rheumatology"},{"key":"R2-7-20210226","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1136\/ard.2006.062760","article-title":"Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists.","volume":"66","author":"Askling","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"R3-7-20210226","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","article-title":"Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials.","volume":"295","author":"Bongartz","year":"2006","journal-title":"JAMA"},{"key":"R4-7-20210226","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1002\/art.22504","article-title":"Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists.","volume":"56","author":"Curtis","year":"2007","journal-title":"Arthritis Rheum"},{"key":"R5-7-20210226","doi-asserted-by":"crossref","first-page":"4226","DOI":"10.1002\/art.23050","article-title":"Drug-specific and time-dependent risks of bacterial infection among patients with rheumatoid arthritis who were exposed to tumor necrosis factor alpha antagonists.","volume":"56","author":"Curtis","year":"2007","journal-title":"Arthritis Rheum"},{"key":"R6-7-20210226","first-page":"1","article-title":"National Hospital Discharge Survey: 2005 annual summary with detailed diagnosis and procedure data.","volume":"13","author":"DeFrances","year":"2007","journal-title":"Vital Health Stat"},{"key":"R7-7-20210226","doi-asserted-by":"crossref","first-page":"2896","DOI":"10.1002\/art.22808","article-title":"Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies.","volume":"56","author":"Dixon","year":"2007","journal-title":"Arthritis Rheum"},{"key":"R8-7-20210226","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1002\/art.21978","article-title":"Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register.","volume":"54","author":"Dixon","year":"2006","journal-title":"Arthritis Rheum"},{"key":"R9-7-20210226","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1001\/archinte.1995.00430150071008","article-title":"The incidence of herpes zoster.","volume":"155","author":"Donahue","year":"1995","journal-title":"Arch Intern Med"},{"key":"R10-7-20210226","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1002\/art.10524","article-title":"Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study.","volume":"46","author":"Doran","year":"2002","journal-title":"Arthritis Rheum"},{"key":"R11-7-20210226","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/00005650-199801000-00004","article-title":"Comorbidity measures for use with administrative data.","volume":"36","author":"Elixhauser","year":"1998","journal-title":"Med Care"},{"key":"R12-7-20210226","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1002\/1529-0131(199904)42:3<415::AID-ANR4>3.0.CO;2-Z","article-title":"The epidemiology of rheumatoid arthritis in Rochester, Minnesota, 1955-1985.","volume":"42","author":"Gabriel","year":"1999","journal-title":"Arthritis Rheum"},{"key":"R13-7-20210226","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1185\/030079906X80341","article-title":"Real-world utilization of DMARDs and biologics in rheumatoid arthritis: the RADIUS (Rheumatoid Arthritis Disease-Modifying Anti-Rheumatic Drug Intervention and Utilization Study) study.","volume":"22","author":"Gibofsky","year":"2006","journal-title":"Curr Med Res Opin"},{"key":"R14-7-20210226","first-page":"1243","article-title":"Does age bias the aggressive treatment of elderly patients with rheumatoid arthritis?","volume":"32","author":"Harrison","year":"2005","journal-title":"J Rheumatol"},{"key":"R15-7-20210226","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1001\/jama.2009.722","article-title":"Acid-suppressive medication use and the risk for hospital-acquired pneumonia.","volume":"301","author":"Herzig","year":"2009","journal-title":"JAMA"},{"key":"R16-7-20210226","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1097\/00005650-199809000-00005","article-title":"Agreement between administrative files and written medical records: a case of the Department of Veterans Affairs.","volume":"36","author":"Kashner","year":"1998","journal-title":"Med Care"},{"key":"R17-7-20210226","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1002\/art.23913","article-title":"Use of nonbiologic disease-modifying antirheumatic drugs and risk of infection in patients with rheumatoid arthritis.","volume":"59","author":"Lacaille","year":"2008","journal-title":"Arthritis Rheum"},{"key":"R18-7-20210226","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1093\/rheumatology\/keh464","article-title":"Update on the British Society for Rheumatology guidelines for prescribing TNFalpha blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001).","volume":"44","author":"Ledingham","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"R19-7-20210226","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1002\/art.21386","article-title":"Infections in patients with rheumatoid arthritis treated with biologic agents.","volume":"52","author":"Listing","year":"2005","journal-title":"Arthritis Rheum"},{"key":"R20-7-20210226","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1093\/rheumatology\/ken450a","article-title":"British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of rheumatoid arthritis (after the first 2 years).","volume":"48","author":"Luqmani","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"R21-7-20210226","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1086\/598331","article-title":"Herpes zoster risk factors in a national cohort of veterans with rheumatoid arthritis.","volume":"48","author":"McDonald","year":"2009","journal-title":"Clin Infect Dis"},{"key":"R22-7-20210226","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1136\/bmj.290.6484.1797","article-title":"Ten year mortality and causes of death in patients with rheumatoid arthritis.","volume":"290","author":"Mutru","year":"1985","journal-title":"Br Med J (Clin Res Ed)"},{"key":"R23-7-20210226","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1046\/j.1524-4733.2002.52013.x","article-title":"Is sepsis accurately coded on hospital bills?","volume":"5","author":"Ollendorf","year":"2002","journal-title":"Value Health"},{"key":"R24-7-20210226","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1111\/j.1475-6773.2005.00444.x","article-title":"Measuring diagnoses: ICD code accuracy.","volume":"40","author":"O'Malley","year":"2005","journal-title":"Health Serv Res"},{"key":"R25-7-20210226","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1002\/art.23721","article-title":"American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis.","volume":"59","author":"Saag","year":"2008","journal-title":"Arthritis Rheum"},{"key":"R26-7-20210226","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1002\/art.22890","article-title":"Treatment of older adult patients diagnosed with rheumatoid arthritis: improved but not optimal.","volume":"57","author":"Schmajuk","year":"2007","journal-title":"Arthritis Rheum"},{"key":"R27-7-20210226","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.jclinepi.2006.07.011","article-title":"Veteran's affairs hospital discharge databases coded serious bacterial infections accurately.","volume":"60","author":"Schneeweiss","year":"2007","journal-title":"J Clin Epidemiol"},{"key":"R28-7-20210226","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1002\/art.22600","article-title":"Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis.","volume":"56","author":"Schneeweiss","year":"2007","journal-title":"Arthritis Rheum"},{"key":"R29-7-20210226","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1682\/JRRD.2006.07.0081","article-title":"Department of Veterans Affairs-Medicare dual beneficiaries with stroke: where do they get care?","volume":"45","author":"Shen","year":"2008","journal-title":"J Rehabil Res Dev"},{"key":"R30-7-20210226","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1002\/art.20827","article-title":"Accuracy of Veterans Administration databases for a diagnosis of rheumatoid arthritis.","volume":"51","author":"Singh","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"Suppl 51","key":"R31-7-20210226","first-page":"S35","article-title":"Mortality in rheumatoid arthritis: 2008 update.","volume":"26","author":"Sokka","year":"2008","journal-title":"Clin Exp Rheumatol"},{"key":"R32-7-20210226","first-page":"1679","article-title":"Performance of a rheumatoid arthritis records-based index of severity.","volume":"32","author":"Ting","year":"2005","journal-title":"J Rheumatol"},{"key":"R33-7-20210226","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1086\/383317","article-title":"Granulomatous infectious diseases associated with tumor necrosis factor antagonists.","volume":"38","author":"Wallis","year":"2004","journal-title":"Clin Infect Dis"},{"key":"R34-7-20210226","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1097\/MLR.0b013e318070c6e2","article-title":"Who pays when VA users are hospitalized in the private sector? Evidence from three data sources.","volume":"45","author":"West","year":"2007","journal-title":"Med Care"},{"key":"R35-7-20210226","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1002\/art.21568","article-title":"Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy.","volume":"54","author":"Wolfe","year":"2006","journal-title":"Arthritis Rheum"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0b013e318211106a","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:44:49Z","timestamp":1786041889000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00005792-201103000-00007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0b013e318211106a","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2011,3]]}}}